Iron Metabolism in Prostate Cancer; From Basic Science to New Therapeutic Strategies

Vela, Driton

doi:10.3389/fonc.2018.00547

Cited by 30 publications

(20 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a therapeutic strategy for cancer and CSCs, attention is recently focused on iron metabolism [35,36,37]. We confirmed some basic effects by iron chelator.…”

Section: Discussionsupporting

confidence: 73%

A Novel Combination Cancer Therapy with Iron Chelator Targeting Cancer Stem Cells via Suppressing Stemness

Katsura

Ohara

Noma

et al. 2019

Cancers

View full text Add to dashboard Cite

Excess iron causes cancer and is thought to be related to carcinogenesis and cancer progression including stemness, but the details remain unclear. Here, we hypothesized that stemness in cancer is related to iron metabolism and that regulating iron metabolism in cancer stem cells (CSCs) may be a novel therapy. In this study, we used murine induced pluripotent stem cells that expressed specific stem cell genes such as Nanog, Oct3/4, Sox2, Klf4, and c-Myc, and two human cancer cell lines with similar stem cell gene expression. Deferasirox, an orally available iron chelator, suppressed expression of stemness markers and spherogenesis of cells with high stemness status in vitro. Combination therapy had a marked antitumor effect compared with deferasirox or cisplatin alone. Iron metabolism appears important for maintenance of stemness in CSCs. An iron chelator combined with chemotherapy may be a novel approach via suppressing stemness for CSC targeted therapy.

show abstract

“…As a therapeutic strategy for cancer and CSCs, attention is recently focused on iron metabolism [35,36,37]. We confirmed some basic effects by iron chelator.…”

Section: Discussionsupporting

confidence: 73%

A Novel Combination Cancer Therapy with Iron Chelator Targeting Cancer Stem Cells via Suppressing Stemness

Katsura

Ohara

Noma

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Beyond the tumorigenic potential of iron, tumor cells also exhibit a shift in iron homeostasis toward exacerbated intracellular iron sequestration through increasing uptake and storage, downmodulating export, or both mechanisms. This is evidenced by the downmodulation of FPN1 and overexpression of its natural inhibitor, hepcidin, in a variety of solid tumors, e.g., breast, ovarian, and prostate cancer [ 64 , 65 , 66 , 67 , 68 ]. When disturbed, the ferroportin–hepcidin axis indeed promotes breast-tumor growth mediated by BMP6- and IL-6-induced hepatic hepcidin, thus leading to an increase in the intracellular LIP [ 69 ].…”

Section: Iron Oxide-driven Biological Activities: Cellular Iron Mementioning

confidence: 99%

The Intrinsic Biological Identities of Iron Oxide Nanoparticles and Their Coatings: Unexplored Territory for Combinatorial Therapies

2020

View full text Add to dashboard Cite

Over the last 20 years, iron oxide nanoparticles (IONPs) have been the subject of increasing investigation due to their potential use as theranostic agents. Their unique physical properties (physical identity), ample possibilities for surface modifications (synthetic identity), and the complex dynamics of their interaction with biological systems (biological identity) make IONPs a unique and fruitful resource for developing magnetic field-based therapeutic and diagnostic approaches to the treatment of diseases such as cancer. Like all nanomaterials, IONPs also interact with different cell types in vivo, a characteristic that ultimately determines their activity over the short and long term. Cells of the mononuclear phagocytic system (macrophages), dendritic cells (DCs), and endothelial cells (ECs) are engaged in the bulk of IONP encounters in the organism, and also determine IONP biodistribution. Therefore, the biological effects that IONPs trigger in these cells (biological identity) are of utmost importance to better understand and refine the efficacy of IONP-based theranostics. In the present review, which is focused on anti-cancer therapy, we discuss recent findings on the biological identities of IONPs, particularly as concerns their interactions with myeloid, endothelial, and tumor cells. Furthermore, we thoroughly discuss current understandings of the basic molecular mechanisms and complex interactions that govern IONP biological identity, and how these traits could be used as a stepping stone for future research.

show abstract

“…This has made it a desirable target for cancer treatment and prevention. 19 Previous studies have shown that iron metabolism may contribute to certain cancers, including lung cancer, 20 leukemia, 21 prostate cancer, 22 and kidney cancer. 23 However, the prognostic signature of iron metabolism in GC needs to be adequately explored.…”

Section: Discussionmentioning

confidence: 99%

<p>An Iron Metabolism-Related <em>SLC22A17</em> for the Prognostic Value of Gastric Cancer</p>

Wei¹,

Gao²,

Qin³

et al. 2020

OTT

View full text Add to dashboard Cite

Purpose Gastric cancer (GC) is a type of malignant cancer with a poor prognosis. The iron’s metabolism plays an important role in the process of GC. The aim of this study was to evaluate the effectiveness of SLC22A17 , associated with iron metabolism, in predicting the prognosis of GC patients. Materials and Methods We analyzed genes related to iron metabolism of gastric cancer mRNA-seq data from TCGA database. We identified an iron metabolism-related SLC22A17 as an independent prognostic factor using univariate and multivariate Cox regression analysis. Results Further research showed that SLC22A17 was related with many pathways involved in the process of gastric cancer, and the expression was associated with diverse cancer-infiltrating immune cells. The expression of SLC22A17 was associated with T (Topography). Conclusion We validated that SLC22A17 associated with iron metabolism could serve as a prognostic biomarker for GC patients.

show abstract

Iron Metabolism in Prostate Cancer; From Basic Science to New Therapeutic Strategies

Cited by 30 publications

References 131 publications

A Novel Combination Cancer Therapy with Iron Chelator Targeting Cancer Stem Cells via Suppressing Stemness

A Novel Combination Cancer Therapy with Iron Chelator Targeting Cancer Stem Cells via Suppressing Stemness

The Intrinsic Biological Identities of Iron Oxide Nanoparticles and Their Coatings: Unexplored Territory for Combinatorial Therapies

<p>An Iron Metabolism-Related <em>SLC22A17</em> for the Prognostic Value of Gastric Cancer</p>

Contact Info

Product

Resources

About